BioNTech (NASDAQ:BNTX – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 19th. Analysts expect the company to announce earnings of $0.38 per share for the quarter. BioNTech has set its FY 2025 guidance at EPS.Parties that are interested in participating in the company’s conference call can do so using this link.
BioNTech (NASDAQ:BNTX – Get Free Report) last released its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech’s revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.90 EPS. On average, analysts expect BioNTech to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
BioNTech Stock Up 2.1 %
NASDAQ:BNTX opened at $99.47 on Monday. The company has a market cap of $23.85 billion, a PE ratio of -47.37 and a beta of 0.30. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $115.49 and its two-hundred day moving average is $113.37.
Analyst Ratings Changes
Check Out Our Latest Analysis on BioNTech
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Featured Stories
- Five stocks we like better than BioNTech
- Growth Stocks: What They Are, What They Are Not
- How to Build the Ultimate Everything ETF Portfolio
- What Are Dividend Champions? How to Invest in the Champions
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.